With recent evidence affirming the low-risk safety profile of GLP-1 receptor agonists, policymakers are urged to address reimbursement barriers and enhance access to obesity specialists. As anxiety about long-term effects persists among parents and clinicians, targeted educational campaigns aim to build trust and support treatment acceptance. Over the next year, as these initiatives unfold, improvements in stakeholder confidence will likely lead to greater uptake of these effective weight management therapies.
Title not available for this citation.
“Recent observational studies report conflicting evidence on whether semaglutide use is associated with non-arteritic anterior ischemic optic neuropathy (NAION).”
Title not available for this citation.
“Current evidence does not support a causal relationship between semaglutide and NAION.”
Title not available for this citation.
“The divergent findings are most plausibly explained by confounding by indication: patients prescribed semaglutide tend to have more severe diabetes, obesity, and cardiovascular disease, all independent risk factors for NAION.”
Title not available for this citation.
“Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, has shown substantial weight loss effects in clinical trials.”
Title not available for this citation.
“In this real-world cohort, tirzepatide at 2.5 mg and 5.0 mg led to substantial improvements in weight and metabolic health, with good tolerability.”
Title not available for this citation.
“Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are emerging as a cornerstone in the management of type 2 diabetes and obesity.”
Title not available for this citation.
“A lower overall rate of postoperative pseudarthrosis was reported among GLP-1RA users compared with matched controls (15.9% vs 20.2%; p = 0.0129).”
Title not available for this citation.
“Patients not receiving GLP-1RAs had a significantly higher 30-day hardware removal rate compared with GLP-1RA users (odds ratio 1.953; p = 0.028).”
Title not available for this citation.
“Current literature suggests that perioperative GLP-1RA use is associated with lower rates of pseudarthrosis after hindfoot arthrodesis.”
Title not available for this citation.
“Gynecological hemorrhagic events were reported in 0.60% of tirzepatide cases and 0.62% of semaglutide cases.”
Title not available for this citation.
“The ROR for tirzepatide versus semaglutide was 0.97 (95% CI = 0.82-1.14), indicating no statistically significant difference in reporting odds.”
Title not available for this citation.
“A significant disparity in reporter sources was observed, with 94.6% of tirzepatide reports originating from consumers compared to 53.4% for semaglutide.”
.svg&width=160)